undamentalytics Newsletter
Sign in

Regeneron Pharmaceuticals income statement

In fiscal 2025, Regeneron Pharmaceuticals reported revenue of $14.34bn, up 1.0% on the year before, operating income of $3.58bn (a 24.9% margin) and net income of $4.50bn, or $41.48 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue0.40.50.41.42.12.84.14.95.95.16.68.516.112.213.114.214.316.9
Cost of revenue—————————0.20.4———————
Gross profit—————————4.96.2———————
Research and development0.40.50.50.60.91.31.62.12.11.52.52.62.93.64.45.15.96.6
Selling, general and administrative0.10.10.10.20.30.50.81.21.31.11.31.31.82.12.63.02.72.8
Operating income−0.1−0.1−0.20.50.70.81.31.32.12.52.23.68.94.74.04.03.64.9
Interest expense0.00.00.00.00.00.00.00.00.00.00.00.10.10.10.10.10.00.0
Income before tax−0.1−0.1−0.20.40.70.81.21.32.12.62.43.89.34.94.24.85.25.7
Income tax−0.00.0−0.0−0.30.30.40.60.40.90.10.30.31.30.50.20.40.70.9
Net income−0.1−0.1−0.20.80.40.30.60.91.22.42.13.58.14.34.04.44.54.8
Diluted EPS−$0.85−$1.26−$2.45$6.75$3.72$2.98$5.52$7.70$10.34$21.29$18.46$30.52$71.97$38.22$34.77$38.34$41.48$45.16
Diluted shares (average)—83m91m115m111m113m115m116m116m115m115m115m112m114m114m115m109m107m
EBITDA−0.1−0.1−0.20.50.80.91.31.42.22.72.43.89.25.14.54.54.15.4

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: REGN vs VRTXBIIB vs REGNGILD vs REGNAMGN vs REGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Regeneron Pharmaceuticals.